Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface
- PMID: 14757842
Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface
Abstract
MDM2 inhibits p53 transcriptional activity, favors its nuclear export, and stimulates its degradation. Inhibition of the p53-MDM2 interaction with synthetic molecules should therefore lead to both the nuclear accumulation and the activation of p53 followed by the death of the tumor cells from apoptosis. Inhibitors of the p53-MDM2 interaction might be attractive new anticancer agents that could be used to activate wild-type p53 in tumors. This review describes our current knowledge on the properties of the existing p53-MDM2 antagonists. Because the discovery of modulators of protein-protein interactions is an emerging field in drug discovery, the strategy used for designing inhibitors of the p53-MDM2 interaction could serve as an example for other protein interfaces.
Similar articles
-
DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.Mol Oncol. 2017 Jun;11(6):612-627. doi: 10.1002/1878-0261.12051. Epub 2017 May 2. Mol Oncol. 2017. PMID: 28296148 Free PMC article.
-
Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets?Trends Pharmacol Sci. 2004 Jul;25(7):343-6. doi: 10.1016/j.tips.2004.04.011. Trends Pharmacol Sci. 2004. PMID: 15219971 Review. No abstract available.
-
MDM2 and MDM4: p53 regulators as targets in anticancer therapy.Int J Biochem Cell Biol. 2007;39(7-8):1476-82. doi: 10.1016/j.biocel.2007.03.022. Epub 2007 Apr 8. Int J Biochem Cell Biol. 2007. PMID: 17499002 Free PMC article. Review.
-
Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.J Med Chem. 2012 Nov 26;55(22):9630-42. doi: 10.1021/jm300969t. Epub 2012 Oct 19. J Med Chem. 2012. PMID: 23046248
-
Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.Med Res Rev. 2016 Sep;36(5):789-844. doi: 10.1002/med.21393. Epub 2016 Jun 15. Med Res Rev. 2016. PMID: 27302609 Review.
Cited by
-
MDM2 promotes genome instability by ubiquitinating the transcription factor HBP1.Oncogene. 2019 Jun;38(24):4835-4855. doi: 10.1038/s41388-019-0761-2. Epub 2019 Feb 28. Oncogene. 2019. PMID: 30816344 Free PMC article.
-
Impact of Reactive Oxygen and Nitrogen Species Produced by Plasma on Mdm2-p53 Complex.Int J Mol Sci. 2021 Sep 3;22(17):9585. doi: 10.3390/ijms22179585. Int J Mol Sci. 2021. PMID: 34502494 Free PMC article.
-
Heterogeneous Hydration of p53/MDM2 Complex.J Chem Theory Comput. 2014 Mar 11;10(3):1302-1313. doi: 10.1021/ct400967m. Epub 2014 Jan 31. J Chem Theory Comput. 2014. PMID: 24803860 Free PMC article.
-
Synthesis of a Macrocycle Based on Linked Amino Acid Mimetics (LAAM).Tetrahedron Lett. 2013 Oct 23;54(43):5799-5801. doi: 10.1016/j.tetlet.2013.08.041. Tetrahedron Lett. 2013. PMID: 25110365 Free PMC article.
-
A small-molecule inhibitor, 5'-O-tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivo.Anticancer Agents Med Chem. 2013 May;13(4):532-45. doi: 10.2174/1871520611313040002. Anticancer Agents Med Chem. 2013. PMID: 22292771 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous